State of Alaska Department of Revenue Acquires 17,115 Shares of Boston Scientific Corporation $BSX

State of Alaska Department of Revenue lifted its holdings in Boston Scientific Corporation (NYSE:BSX) by 11.8% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 162,750 shares of the medical equipment provider’s stock after purchasing an additional 17,115 shares during the quarter. State of Alaska Department of Revenue’s holdings in Boston Scientific were worth $7,104,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Kelleher Financial Advisors bought a new position in Boston Scientific in the 2nd quarter valued at about $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific during the 1st quarter valued at about $28,000. Nvwm LLC raised its position in shares of Boston Scientific by 526.2% during the 3rd quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 542 shares in the last quarter. Rakuten Securities Inc. bought a new stake in shares of Boston Scientific during the 2nd quarter worth about $30,000. Finally, Cassaday & Co Wealth Management LLC acquired a new stake in shares of Boston Scientific in the 1st quarter worth approximately $32,000. 89.07% of the stock is currently owned by institutional investors.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger bought 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares of the company’s stock, valued at $816,644.40. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired 194,522 shares of company stock valued at $9,385,210 in the last quarter. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group decreased their price objective on shares of Boston Scientific from $71.00 to $57.00 and set a “buy” rating for the company in a report on Tuesday, July 14th. Raymond James Financial reiterated an “outperform” rating and set a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research note on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $60.00 target price (down from $75.00) on shares of Boston Scientific in a report on Thursday, July 30th. Oppenheimer cut their target price on Boston Scientific from $85.00 to $65.00 and set an “outperform” rating for the company in a research report on Monday, September 21st. Finally, Leerink Partners decreased their price target on Boston Scientific from $60.00 to $55.00 in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $68.23.

Boston Scientific Price Performance

NYSE:BSX opened at $44.17 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The business’s 50-day moving average price is $46.16 and its 200 day moving average price is $49.80. Boston Scientific Corporation has a 52-week low of $41.38 and a 52-week high of $105.65. The firm has a market cap of $64.02 billion, a P/E ratio of 17.88, a PEG ratio of 1.04 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same period in the prior year, the company earned $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.24 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.